RPL17 and Miyoshi myopathy: Preclinical data have confirmed the important role of the PD-1 pathway in immune evasion by MM cells22, anti-PD1 and anti-PD-L1 monoclonal antibodies exhibited objective responses and antitumor activity in relapsed and refractory MM in phase I studies23,24.